 Shares of Surface Oncology Inc. NASDAQ: SURF, a clinical-stage biopharma company, gained more than 19 in the extended session on Tuesday. What Happened: The spike in shares came after the Cambridge, Massachusetts-based company said Tuesday that one of its lead therapeutic candidates, SRF617, has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of patients with pancreatic cancer. 